OCX - Oncocyte Corporation
0 0%
Share volume: 0
Last Updated:
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.05%
PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2025 | |
|---|---|---|
| Fiscal Quarter | Q1 2025 | |
| Report Date | 05-12-2025 | |
| Assets | ||
| Total Assets | 60.360 M | |
| Current Assets | 36.263 M | |
| Inventories | 459.000 K | |
| Other Current Assets | 0.000 | |
| Short Term Investments | 0.000 | |
| Total Receivables | 0.000 | |
| Current Cash | 31.029 M | |
| Total Non-current Assets | 0.000 | |
| Property Plant Equipment | 0.000 | |
| Other Assets | 24.097 M | |
| Intangible Assets | 0.000 | |
| Goodwill | 0.000 | |
| Liabilities and shareholders’ equity | ||
| Total Liabilities and shareholders’ equity | 60.360 M | |
| Total liabilities | 50.142 M | |
| Total current liabilities | 9.683 M | |
| Accounts Payable | 4.206 M | |
| Other liabilities | 38.385 M | |
| Current long term debt | 0.000 | |
| Long term debt | 0.000 | |
| Other liabilities | 38.385 M | |
| Minority interest | 0.000 | |
| Total Shareholder equity | 10.218 M | |
| Common stock | 367.387 M | |
| Retained earnings | -357.210 M |